NCT02541383 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.
- id
- FG000
- title
- VTd Only
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.
- id
- FG001
- title
- DVTd Only * Arm/Group Title: Characters Remaining: 91
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation
- id
- FG002
- title
- VTd-OBS
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy
- id
- FG003
- title
- VTd-DARA
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation.
- id
- FG004
- title
- DVTd-OBS
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy.
- id
- FG005
- title
- DVTd-DARA
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 50
- group Id
- FG001
- num Subjects
- 37
- group Id
- FG002
- num Subjects
- 48
- group Id
- FG003
- num Subjects
- 41
- group Id
- FG004
- num Subjects
- 21
- group Id
- FG005
- num Subjects
- 25
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 6
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Consent withdrawn
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Sponsor's decision
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 114
- group Id
- FG001
- num Subjects
- 85
- group Id
- FG002
- num Subjects
- 215
- group Id
- FG003
- num Subjects
- 213
- group Id
- FG004
- num Subjects
- 229
- group Id
- FG005
- num Subjects
- 229
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 53
- group Id
- FG001
- num Subjects
- 38
- group Id
- FG002
- num Subjects
- 165
- group Id
- FG003
- num Subjects
- 170
- group Id
- FG004
- num Subjects
- 205
- group Id
- FG005
- num Subjects
- 204
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 61
- group Id
- FG001
- num Subjects
- 47
- group Id
- FG002
- num Subjects
- 50
- group Id
- FG003
- num Subjects
- 43
- group Id
- FG004
- num Subjects
- 24
- group Id
- FG005
- num Subjects
- 25
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.
- id
- FG000
- title
- VTd Only
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), not re-randomized in maintenance phase.
- id
- FG001
- title
- DVTd Only * Arm/Group Title: Characters Remaining: 91
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation
- id
- FG002
- title
- VTd-OBS
- description
- All patients randomized to the VTd group (Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy
- id
- FG003
- title
- VTd-DARA
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to observation.
- id
- FG004
- title
- DVTd-OBS
- description
- All patients randomized to the DVTd group (Daratumumab, Bortezomib (VELCADE), Thalidomide, and Dexamethasone) at rando 1 (even those who didn't receive any study treatment), re-randomized to daratumumab monotherapy.
- id
- FG005
- title
- DVTd-DARA
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 50
- group Id
- FG001
- num Subjects
- 37
- group Id
- FG002
- num Subjects
- 48
- group Id
- FG003
- num Subjects
- 41
- group Id
- FG004
- num Subjects
- 21
- group Id
- FG005
- num Subjects
- 25
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 6
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Consent withdrawn
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Sponsor's decision
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 114
- group Id
- FG001
- num Subjects
- 85
- group Id
- FG002
- num Subjects
- 215
- group Id
- FG003
- num Subjects
- 213
- group Id
- FG004
- num Subjects
- 229
- group Id
- FG005
- num Subjects
- 229
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 53
- group Id
- FG001
- num Subjects
- 38
- group Id
- FG002
- num Subjects
- 165
- group Id
- FG003
- num Subjects
- 170
- group Id
- FG004
- num Subjects
- 205
- group Id
- FG005
- num Subjects
- 204
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 61
- group Id
- FG001
- num Subjects
- 47
- group Id
- FG002
- num Subjects
- 50
- group Id
- FG003
- num Subjects
- 43
- group Id
- FG004
- num Subjects
- 24
- group Id
- FG005
- num Subjects
- 25
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle